MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.
{iframe}https://www.maxcyte.com/maxcyte-announces-multi-drug-clinical-commercial-agreement-with-kite-a-gilead-company/?platform=hootsuite{/iframe}